{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:58:40Z","timestamp":1791115120329,"version":"4.1.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,7,1]]},"abstract":"<jats:p>The V617F JAK2 mutation reported in Ph-negative myeloproliferative diseases (MPDs) induces the constitutive activation of JAK2, which produces an increased phosphorylation of signal transducer activator of transcription (STAT). In this study, we have analyzed a series of 114 patients (54 with polycythemia vera [PV], 44 with essential thrombocythemia [ET], 12 with idiopathic myelofibrosis [IM], and 4 with myelofibrosis secondary to MPD) for the expression pattern of phosphorylated STAT-3 and STAT-5 (pSTAT-3 and pSTAT-5, respectively) by immunostaining bone marrow biopsies. We found 3 specific patterns of pSTAT-3 and pSTAT-5 expression, significantly different from the normal staining pattern: uniformly increased pSTAT-3 and pSTAT-5 expression in PV, increased pSTAT-3 and reduced pSTAT-5 expression in ET, and uniformly reduced pSTAT-3 and pSTAT-5 expression in IM. A moderate increase of pSTAT-3 and pSTAT-5 expression was observed in secondary forms of erythrocytosis and thrombocytosis. In all evaluated MPDs, the pSTAT-5 and pSTAT-3 expression pattern was not influenced by the presence of V617F JAK2 mutation. These findings underline the importance of bone marrow histology in the differential diagnosis of Ph-negative MPD and support the hypothesis that V617F mutation simply contributes with other molecular defects in allowing the PV, ET, or IM phenotype to emerge.<\/jats:p>","DOI":"10.1182\/blood-2007-01-069237","type":"journal-article","created":{"date-parts":[[2007,3,21]],"date-time":"2007-03-21T20:39:37Z","timestamp":1174509577000},"page":"354-359","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":70,"title":["Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation"],"prefix":"10.1182","volume":"110","author":[{"given":"Luciana","family":"Teofili","sequence":"first","affiliation":[{"name":"Departments ofHematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Martini","sequence":"additional","affiliation":[{"name":"Pathology of the Catholic University of Rome, Italy, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonia","family":"Cenci","sequence":"additional","affiliation":[{"name":"Departments ofHematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Petrucci","sequence":"additional","affiliation":[{"name":"Pathology of the Catholic University of Rome, Italy, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Torti","sequence":"additional","affiliation":[{"name":"Departments ofHematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Storti","sequence":"additional","affiliation":[{"name":"the Department of Hematology of the Catholic University of Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Guidi","sequence":"additional","affiliation":[{"name":"the Department of Hematology of the Catholic University of Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Leone","sequence":"additional","affiliation":[{"name":"Departments ofHematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Maria","family":"Larocca","sequence":"additional","affiliation":[{"name":"Pathology of the Catholic University of Rome, Italy, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111901031810300_B1","doi-asserted-by":"crossref","first-page":"22788","DOI":"10.1074\/jbc.C500138200","article-title":"Identification of an acquired JAK2 mutation in polycythemia vera.","volume":"280","author":"Zhao","year":"2005","journal-title":"J Biol Chem"},{"key":"2019111901031810300_B2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"2019111901031810300_B3","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"2019111901031810300_B4","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"2019111901031810300_B5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"2019111901031810300_B6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0092-8674(00)81013-2","article-title":"Fetal anemia and apoptosis of red cell progenitors in Stat5a-\/-5b-\/- mice: a direct role for Stat5 in Bcl-X(L) induction.","volume":"98","author":"Socolovsky","year":"1999","journal-title":"Cell"},{"key":"2019111901031810300_B7","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1073\/pnas.94.8.3801","article-title":"Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality.","volume":"94","author":"Takeda","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111901031810300_B8","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1172\/JCI0215650","article-title":"What does Stat3 do?","volume":"109","author":"Levy","year":"2002","journal-title":"J Clin Invest"},{"key":"2019111901031810300_B9","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0301-472X(01)00637-3","article-title":"STAT3 is constitutively active in some patients with polycythemia rubra vera.","volume":"29","author":"Roder","year":"2001","journal-title":"Exp Hematol"},{"key":"2019111901031810300_B10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.exphem.2003.11.003","article-title":"Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera.","volume":"32","author":"Ugo","year":"2004","journal-title":"Exp Hematol"},{"key":"2019111901031810300_B11","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJM197406132902419","article-title":"Bone-marrow responses in polycythemia vera.","volume":"290","author":"Prchal","year":"1974","journal-title":"N Engl J Med"},{"key":"2019111901031810300_B12","first-page":"235","article-title":"Abnormal erythropoiesis in the myeloproliferative disorders: an analysis of underlying cellular and humoral mechanisms.","author":"Eaves","year":"1980","journal-title":"Exp Hematol"},{"key":"2019111901031810300_B13","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood.V95.8.2569","article-title":"Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera.","volume":"95","author":"Temerinac","year":"2000","journal-title":"Blood"},{"key":"2019111901031810300_B14","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1200\/JCO.2002.11.507","article-title":"Overexpression of the polycythemia rubra vera-1 gene in essential thrombocythemia.","volume":"20","author":"Teofili","year":"2002","journal-title":"J Clin Oncol"},{"key":"2019111901031810300_B15","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1056\/NEJM199802263380903","article-title":"Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera.","volume":"338","author":"Moliterno","year":"1998","journal-title":"N Engl J Med"},{"key":"2019111901031810300_B16","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood.V96.2.771","article-title":"Immunohistochemical staining for megakaryocyte c-mpl may complement morphologic distinction between polycythemia vera and secondary erythrocytosis.","volume":"96","author":"Tefferi","year":"2000","journal-title":"Blood"},{"key":"2019111901031810300_B17","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.V100.2.714","article-title":"The expression pattern of c-mpl in megakaryocytes correlates with thrombotic risk in essential thrombocythemia.","volume":"100","author":"Teofili","year":"2002","journal-title":"Blood"},{"key":"2019111901031810300_B18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-2007-996107","article-title":"Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.","volume":"23","author":"Michiels","year":"1997","journal-title":"Semin Thromb Hemost"},{"key":"2019111901031810300_B19","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms.","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"2019111901031810300_B20","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1200\/JCO.2006.08.6884","article-title":"Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.","volume":"25","author":"Teofili","year":"2007","journal-title":"J Clin Oncol"},{"key":"2019111901031810300_B21","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1038\/sj.leu.2404338","article-title":"Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia.","volume":"20","author":"Mesa","year":"2006","journal-title":"Leukemia"},{"key":"2019111901031810300_B22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1055\/s-2006-939433","article-title":"Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders.","volume":"32","author":"Thiele","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"2019111901031810300_B23","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1182\/blood.V83.3.744.744","article-title":"Identification of masked polycythemia vera from patients with idiopathic marked thrombocytosis by endogenous erythroid colony assay.","volume":"83","author":"Shih","year":"1994","journal-title":"Blood"},{"key":"2019111901031810300_B24","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1038\/sj.leu.2401553","article-title":"Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF): a clinicopathological study.","volume":"13","author":"Thiele","year":"1999","journal-title":"Leukemia"},{"key":"2019111901031810300_B25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.exphem.2006.11.012","article-title":"Polycythemia vera is not initiated by JAK2V617F mutation.","volume":"35","author":"Nussenzveig","year":"2007","journal-title":"Exp Hematol"},{"key":"2019111901031810300_B26","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/sj.leu.2404513","article-title":"Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR\/ABL-negative myeloproliferative disorders.","volume":"21","author":"Jost","year":"2007","journal-title":"Leukemia"},{"key":"2019111901031810300_B27","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"2019111901031810300_B28","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJM199802263380902","article-title":"Expression of Bcl-x in erythroid precursors from patients with polycythemia vera.","volume":"338","author":"Silva","year":"1998","journal-title":"N Engl J Med"},{"key":"2019111901031810300_B29","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1084\/jem.20041024","article-title":"Constitutive activation of STAT5A promotes human hematopoietic stem cell self-renewal and erythroid differentiation.","volume":"200","author":"Schuringa","year":"2004","journal-title":"J Exp Med"},{"key":"2019111901031810300_B30","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2005-10-009514","article-title":"Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells.","volume":"108","author":"Garcon","year":"2006","journal-title":"Blood"},{"key":"2019111901031810300_B31","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/blood.V99.9.3220","article-title":"A functional role of Stat3 in in vivo megakaryopoiesis.","volume":"99","author":"Kirito","year":"2002","journal-title":"Blood"},{"key":"2019111901031810300_B32","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1600-0609.2006.00688.x","article-title":"JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status.","volume":"77","author":"Heller","year":"2006","journal-title":"Eur J Haematol"},{"key":"2019111901031810300_B33","doi-asserted-by":"crossref","first-page":"16513","DOI":"10.1074\/jbc.274.23.16513","article-title":"Interleukin-10 receptor signaling through the JAK-STAT pathway: requirement for two distinct receptor-derived signals for anti-inflammatory action.","volume":"274","author":"Riley","year":"1999","journal-title":"J Biol Chem"},{"key":"2019111901031810300_B34","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1042\/BST0341028","article-title":"STAT3-mediated anti-inflammatory signalling.","volume":"34","author":"Murray","year":"2006","journal-title":"Biochem Soc Trans"},{"key":"2019111901031810300_B35","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1053\/j.seminhematol.2005.05.018","article-title":"Idiopathic myelofibrosis.","volume":"42","author":"Barosi","year":"2005","journal-title":"Semin Hematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/1\/354\/482113\/zh801307000354.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/1\/354\/482113\/zh801307000354.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T01:03:33Z","timestamp":1574125413000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/110\/1\/354\/133640\/Different-STAT3-and-STAT5-phosphorylation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,7,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-01-069237","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,1]]}}}